Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy
Public ClinicalTrials.gov record NCT02811627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Predicting Treatment Response to Memantine in Autism Spectrum Disorder Using MR Spectroscopy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Memantine, an N-methyl-D-aspartate receptor antagonist, has been explored as a possible therapeutic agent that reduces the excitatory (glutamate) - inhibitory (gamma amino-butyric acid, GABA) imbalance in autism pathology and improves social and communication deficits. While some studies have shown positive results, a large clinical trial failed to show benefit possibly because different subsets of autism responded differently to the treatment. The investigator proposes a pilot, exploratory, clinical follow-on study using proton magnetic resonance spectroscopy (1H-MRS) to determine whether baseline glutamate/GABA levels in certain regions of the brain may help predict treatment response to Memantine in autistic subjects. At study onset, subjects will be assessed on the behavioral scales such as the Aberrant Behavior Checklist and Clinical Global Impressions scale, followed by MRS imaging. Memantine treatment will be started post imaging. Assessment measures will be repeated at week 12 during treatment. Glutamate and GABA levels in brain regions will be correlated to improvements on assessment measures. Expected results include higher glutamate and/or lower GABA levels in the anterior cingulate cortex at baseline in responders to memantine. If the hypotheses are confirmed, it will provide evidence of a relevant neural biomarker to predict treatment response to memantine with important implications for clinical care including improving individualization of treatments.
Study identification
- NCT ID
- NCT02811627
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2016
- Primary completion
- Mar 31, 2021
- Completion
- Mar 31, 2021
- Last update posted
- Apr 13, 2021
2016 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Missouri | Columbia | Missouri | 65211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Autism Spectrum Disorder trials
Other public records listing Autism Spectrum Disorder. Sorted by last update posted; newest first. Not a recommendation.
- NCT07770152: Semaglutide in Youth With Autism Spectrum Disorder Not yet recruiting
- NCT07758088: Dance, Yoga, And Mindful Movement Training For ASD Not yet recruiting
- NCT07755137: Feasibility, Acceptability, and Preliminary Effectiveness of Cognitive Behavioral Therapy for Depression in Autistic Youth in Clinical Settings Not yet recruiting
- NCT07746921: Smart Inhaler and Remote Asthma Management in Adolescents With Intellectual and Developmental Disabilities Not yet recruiting
- NCT05889273: ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) Active, not recruiting
- NCT03827941: Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02811627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02811627 live on ClinicalTrials.gov.